Ondine Biomedical Inc.
OBIMF
$0.14
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.63% | 10.77% | 49.26% | 50.99% | 97.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.63% | 10.77% | 49.26% | 50.99% | 97.05% |
| Cost of Revenue | 6.72% | 1.31% | 19.80% | 21.18% | 83.00% |
| Gross Profit | 22.81% | 16.67% | 70.32% | 72.28% | 106.96% |
| SG&A Expenses | 1.94% | -3.17% | 51.40% | 53.20% | -19.02% |
| Depreciation & Amortization | 2.52% | -2.68% | -7.40% | -6.32% | -9.14% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.03% | 46.31% | 64.83% | 66.78% | 0.85% |
| Operating Income | -58.14% | -50.21% | -66.61% | -68.58% | 4.27% |
| Income Before Tax | -60.02% | -52.00% | -69.18% | -71.19% | 3.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.02% | -52.00% | -69.18% | -71.19% | 3.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.02% | -52.00% | -69.18% | -71.19% | 3.54% |
| EBIT | -58.14% | -50.21% | -66.61% | -68.58% | 4.27% |
| EBITDA | -56.12% | -48.29% | -67.35% | -69.34% | 4.02% |
| EPS Basic | 11.11% | 15.97% | -10.00% | -10.66% | 22.52% |
| Normalized Basic EPS | 10.96% | 16.00% | -5.13% | -6.33% | 23.16% |
| EPS Diluted | 11.11% | 15.97% | -10.00% | -10.66% | 22.52% |
| Normalized Diluted EPS | 10.96% | 16.00% | -5.13% | -6.33% | 23.16% |
| Average Basic Shares Outstanding | 81.08% | 81.08% | 54.25% | 54.25% | 24.01% |
| Average Diluted Shares Outstanding | 81.08% | 81.08% | 54.25% | 54.25% | 24.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |